Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many mechanistic and product-specific claims (breath-actuation and dosing-strength wording) are unsupported by the provided label excerpts. Some safety-related corticosteroid effects (adrenal, growth, eye conditions) are supported, but other safety claims and multiple label-critical sections (e.g., contraindications/boxed warnings) are not available for comparison.
Category Scores
Accurate Statements
Qvar RediHaler contains beclomethasone dipropionate.
DESCRIPTION: active component ... is beclomethasone dipropionate
Beclomethasone dipropionate works by reducing inflammation in the airways.
CLINICAL PHARMACOLOGY: corticosteroids have anti-inflammatory actions contributing to efficacy
Qvar RediHaler is intended for use as directed by a healthcare professional.
DOSAGE AND ADMINISTRATION: Use only as directed by your physician; PRECAUTIONS/Patient Instructions: use at regular intervals as directed
Qvar RediHaler utilizes a hydrofluoroalkane (HFA) propellant.
DESCRIPTION: propellant HFA-134a (1,1,1,2 tetrafluoroethane) and ethanol
Common side effects associated with Qvar RediHaler can include headache.
ADVERSE REACTIONS: HEADACHE listed
Inhaled corticosteroids can have potential effects on the adrenal glands.
WARNINGS: adrenal insufficiency; PRECAUTIONS: HPA axis suppression/adrenal cortisol production reduction
Inhaled corticosteroids can have potential effects on growth rate.
DOSAGE AND ADMINISTRATION: potential to affect growth in children; PRECAUTIONS: reduction in growth velocity
Inhaled corticosteroids can have potential effects on eye conditions such as cataracts.
PRECAUTIONS: rare instances of cataracts reported
Inhaled corticosteroids can have potential effects on eye conditions such as glaucoma.
PRECAUTIONS: rare instances of glaucoma and increased intraocular pressure reported
Unsupported Statements
Qvar RediHaler is a breath-actuated metered-dose inhaler.
The provided label excerpts do not state 'breath-actuated' or RediHaler-specific device mechanics.
In a breath-actuated metered-dose inhaler, the medication is released when the user inhales.
No provided label excerpt describes breath-triggered release mechanics.
Qvar RediHaler is designed to be breath-actuated, distinguishing it from some other metered-dose inhalers that require manual actuation and coordinated inhalation.
No provided label excerpt contrasts QVAR with manually actuated/coordination-based inhalers.
The breath-actuated design means the user places the mouthpiece in their mouth and inhales deeply and steadily until a dose is released.
No provided label excerpt describes this breath-actuation/dose-release instruction.
Inhaled corticosteroids can increase the risk of pneumonia in patients with COPD.
No provided label excerpts mention COPD or pneumonia risk.
Inhaled corticosteroids can have potential effects on bone mineral density.
No provided label excerpts mention bone mineral density.
Contradictions
Low
AI Statement
Qvar RediHaler is available in different strengths, including 80 mcg per inhalation and 160 mcg per inhalation.
Label Reference
DESCRIPTION and DOSAGE AND ADMINISTRATION excerpts provided describe QVAR 40 mcg and QVAR 80 mcg inhalation aerosols and include dosing regimens where 160 mcg appears as a twice-daily regimen starting dose, not as a stated '160 mcg per inhalation' strength.
Important Omissions
Boxed warnings, contraindications, and complete warnings/precautions details cannot be fully checked because these label sections were not provided in the prompt.
Importance:
High
Drug interaction information, if any, cannot be evaluated because the relevant label section was not provided.
Importance:
Moderate
Administration instructions for the actual QVAR device included in the provided label (e.g., priming by actuating twice, avoid spraying in eyes/face, oral inhalation technique, mouth rinsing) are not addressed by the AI claims beyond generic breath-actuation mechanics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported device-mechanics claims (breath-actuation and inhalation-triggered dosing) and a mischaracterized strength phrasing could lead to misunderstanding of how dosing should be administered. Additional label-critical sections (contraindications/boxed warnings) were not provided, limiting completeness of safety verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported product-mechanics claims (breath-actuated release) and an imprecise/unsupported strength statement ("160 mcg per inhalation").
Suggested Improvement
Remove or rephrase breath-actuation and inhalation-triggered release assertions unless supported by the provided label. Reconcile strength language with the label’s stated QVAR 40 mcg and QVAR 80 mcg products and clarify that 160 mcg appears as a twice-daily dosing regimen rather than a separate per-actuation strength.